![Ellen Donnelly](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ellen Donnelly
Directeur/Membre du Conseil chez
MODUS THERAPEUTICS HOLDING AB
Profil
Ellen K.
Donnelly is Chief Executive Officer at Neumirna Therapeutics ApS since 2025.
Dr. Donnelly is Independent Director at Modus Therapeutics Holding AB since 2020.
Dr. Donnelly is Director at Modus Therapeutics AB since 2019.
Former roles include Chief Executive Officer-Epigenetics Division at Juvenescence Ltd., Chief Executive Officer at Souvien Therapeutics, Chief Executive Officer at Abliva AB, and Independent Director at AlzeCure Pharma AB from 2018 to 2024.
Education includes a doctorate from Yale School of Medicine.
Postes actifs de Ellen Donnelly
| Sociétés | Poste | Début |
|---|---|---|
| MODUS THERAPEUTICS HOLDING AB | Directeur/Membre du Conseil | 01/01/2020 |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops drug for the treatment of severe malaria and sickle cell disease | Directeur/Membre du Conseil | 01/01/2019 |
Neumirna Therapeutics ApS
 Neumirna Therapeutics ApS BiotechnologyHealth Technology Develops RNA therapeutics for disease modification neurological disorders | Directeur Général | 18/09/2025 |
Anciens postes connus de Ellen Donnelly
| Sociétés | Poste | Fin |
|---|---|---|
| ALZECURE PHARMA AB | Directeur/Membre du Conseil | 14/05/2024 |
Souvien Therapeutics
 Souvien Therapeutics BiotechnologyHealth Technology Operates as a biotechnology company that focuses on developing therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration | Directeur Général | - |
Juvenescence Ltd.
 Juvenescence Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Corporate Officer/Principal | - |
| ABLIVA AB | Directeur Général | - |
Formation de Ellen Donnelly
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
23
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Abliva AB
 Abliva AB Pharmaceuticals: MajorHealth Technology Develops medicines for the treatment of mitochondrial diseases | Health Technology |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops drug for the treatment of severe malaria and sickle cell disease | Health Technology |
Modus Therapeutics Holding AB
 Modus Therapeutics Holding AB BiotechnologyHealth Technology Develops sevuparin to treat people suffering from sickle cell disease | Health Technology |
Yale School of Medicine
 Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Juvenescence Ltd.
Juvenescence Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Finance |
AlzeCure Pharma AB
 AlzeCure Pharma AB BiotechnologyHealth Technology Engages in research, development, manufacture and sale of pharmaceutical products for neuro diseases | Health Technology |
Souvien Therapeutics
Souvien Therapeutics BiotechnologyHealth Technology Operates as a biotechnology company that focuses on developing therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration | Health Technology |
Neumirna Therapeutics ApS
Neumirna Therapeutics ApS BiotechnologyHealth Technology Develops RNA therapeutics for disease modification neurological disorders | Health Technology |
